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Commentary
Debate: Subgroup analyses in clinical trials — fun to look at, but
don’t believe them!
Peter Sleight
John Radcliffe Hospital, Oxford, UK
Abstract
Analysis of subgroup results in a clinical trial is surprisingly unreliable, even in a large trial.
This is the result of a combination of reduced statistical power, increased variance and the
play of chance. Reliance on such analyses is likely to be more erroneous, and hence harmful,
than application of the overall proportional (or relative) result in the whole trial to the estimate
of absolute risk in that subgroup. Plausible explanations can usually be found for effects that
are, in reality, simply due to the play of chance. When clinicians believe such subgroup
analyses, there is a real danger of harm to the individual patient.
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Introduction
Large, properly randomized clinical trials have transformed
the quality of the evidence on which we base modern
therapy [1]. The aim of proper randomization is to eliminate
systematic bias in the allocation of the patient to active
versus placebo (or control) therapy. Systematic bias is prob-
able in trials in which the physician in charge of the alloca-
tion has some insight into which treatment his or her patient
will receive. It is particularly likely to occur with envelope
randomization, in which the physician may open the first
envelope, decides that he or she does not like the allocation
and then opens the next envelope. This has happened quite
recently, for example in the CAPP (Captopril Prevention
Project) study [2]. Another similar source of bias is when
randomization is by the day of the week, or by hospital A
versus hospital B. In such cases the physician can again
influence the allocation. Large effects can result from such
seemingly small biases, even on the main results of the trial.
Such biases are exaggerated in any subgroup analyses. For
this reason many studies use computer allocation, with ran-
domization only after all the necessary entry/baseline data
have been collected at the randomization centre, for
example by telephone (as in the ISIS [International Study of
Infarct Survival] trials [3]) or by some form of fax system (as
in the Heart Outcomes Prevention Evaluation [HOPE]
study, which used computer-scanned fax entry [4]).
Physicians, particularly those in cardiovascular speciali-
ties, have embraced the concept of randomized trials with
enthusiasm. However, they have not fully appreciated the
extent to which the play of chance can produce erroneous
results, even if strenuous efforts have been made to
reduce all bias. After all, a P value of 0.05 means that
there is a 1 in 20 chance that the result may be wrong.
These are not extreme odds – many people are happy to
back horses at this level.Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Sleight
The play of chance is even more likely to produce spurious
results when we examine subgroups in a trial, because of
the diminished power to detect real differences, the
increase in the variance around the mean estimate, and
the increasing statistical likelihood of a false finding when
many subgroups are examined. If we divide a large multi-
centre international trial with a negative result into 40 sub-
groups (by country, age, sex, blood pressure, severity of
disease, treatment, etc), then (at P < 0.05) we would
expect a positive result in two subgroups.
Erroneous interpretation of subgroup analyses
The following are examples of erroneous interpretation of
subgroup analyses that have caused harm to patients.
Restriction of thrombolytic therapy to anterior infarction
In the early trials of thrombolytic therapy in acute myocar-
dial infarction (MI), treatment with streptokinase was
clearly effective in reducing mortality in patients with ante-
rior infarction, who were at higher risk. This at first led to
the erroneous conclusion that thrombolytic therapy did not
work in inferior infarction.
As more data accumulated it became obvious that lytic
therapy was also effective in inferior infarction. Of course,
as with any effective treatment, it is necessary to balance
the benefit against the risk of treatment. In very low risk
small infarctions this risk may outweigh the benefit,
although for most MIs some form of reperfusion is best [5].
Restriction in use of b b-blockade after myocardial infarction
to only anterior infarction
In the same way, the early studies of b-blockade after MI
showed benefit in patients with anterior MI, but only a non-
significant trend toward benefit in patients with inferior MI
(who had fewer events overall). It can readily be shown that,
when the number of events available for analysis is
increased by performing a meta-analysis of all of the studies
[6], b-blocker therapy is beneficial in inferior infarction.
Astrology in the International Study of Infarct
Survival trials
In retrospect, perhaps one of the most important results in
the ISIS trials was the analysis of the results by astrological
star sign. All of the patients had their date of birth entered
as an important ‘identifier’. We were therefore able to
divide our population into 12 subgroups by astrological
star sign. Even in a highly positive trial such as ISIS-2 [3], in
which the overall statistical benefit for aspirin over placebo
was extreme (P < 0.00001), division into only 12 sub-
groups threw up two (Gemini and Libra) for which aspirin
had a nonsignificantly adverse effect (9% ± 13%)
Of course most physicians (but not all!) laughed when
they were presented with these results. However, when
presented with other less ridiculous subgroup analyses
they are likely to believe the results, and forget the
example from astrology, particularly if the result can be jus-
tified by some pet theory.
When one divides a trial by a seemingly more legitimate
grouping (eg by the individual countries in a multinational
study), then it is highly probable that a negative or neutral
result will be seen in one country. Indeed, this was a point
of discussion during the 1 May 2000 US Food and Drug
Administration hearings (Yusuf S, personal communica-
tion) on the results of the recent HOPE study [4], in which
ramipril had no significant effect in the US participants.
We have seen similar results in the ISIS trials, but did not
report these because of the possibility of harm caused by
misinterpretation of such statistical ‘flukes’ (and hence a
failure to use a useful treatment in that country).
ISIS-2 was carried out in 16 countries. For the streptoki-
nase randomization, two countries had nonsignificantly
negative results, and a single (different) country was non-
significantly negative for aspirin.
There is no plausible explanation for such findings except
for the entirely expected operation of the statistical play of
chance. Of course, another reasonable explanation for
negative or curious results in a subgroup is that the statis-
tical power to detect a result is reduced by either a low
event rate (eg in a low-risk subgroup such as young hyper-
tensive persons) or by a low number of subjects in a par-
ticular subgroup (eg old age or female sex).
It is very important to realize that lack of a statistically sig-
nificant effect is not evidence of lack of a real effect.
Unfortunately, this error is often made by physicians.
What is the best way to estimate benefit in a
subgroup?
One way to estimate the benefit of a particular treatment in
a subgroup is to prespecify that an analysis will be done in
particular subgroups (eg high versus low risk, high versus
moderate versus mild hypertension) and to prespecify what
is expected. Such analyses carry more weight than retro-
spective analyses that, if positive, are used to support
some hypothesis. Another way is to apply the overall pro-
portional (relative) risk reduction by treatment X (obtained
from the whole trial) and then to apply this to the absolute
risk in the subgroup of interest. Although possibly counter
intuitive, this is more reliable statistically than examining the
actual result obtained on that subgroup in the trial in ques-
tion [1,7]. The best estimate of risk in such a subgroup
might be from large overviews of the condition, rather than
from the trial itself, particularly if the subgroup is small.
In general it is unlikely that the results in a particular sub-
group are qualitatively different from those of the main trial
result, although they might well be quantitatively differentc
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in, say, young versus older individuals, or higher versus
lower risk groups.
Undue emphasis on a particular subgroup
The GUSTO (Global Use of Strategies to Open Occluded
Coronary Arteries) trial [8] compared two tissue plasmino-
gen activator (t-PA)-based regimens with two streptoki-
nase-based regimens for the thrombolytic treatment of MI.
Before the trial results were known, the investigators had
hoped that the combination arm with streptokinase and
t-PA would be the best. In the event, accelerated t-PA was
better and hence was emphasized. Indirect comparisons
of various trials suggested that there was little difference
between the various agents. In a later analysis of all the
data from ISIS-3, Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto miocardico (GISSI)-2 and
GUSTO, we concluded that there was no significant
superiority of t-PA over streptokinase, despite its undoubt-
edly better lysis rate if 90 min is selected (by 3 h, the
patency rates are similar).
I have also been concerned that t-PA was significantly
superior to streptokinase only in North American patients,
but that this was not so in the rest of the world (approxi-
mately 20000 randomized in each group) [8]. This might
have been caused by chance, but also might have been
because of a North American tendency to greater with-
drawal from streptokinase if hypotension occurred, which is
less likely to occur in non-American centres that are more
familiar with the hypotension that commonly occurs with
streptokinase [9]. I also argued that the lower blood pres-
sure with streptokinase might have protected against cere-
bral haemorrhage, which was significantly higher with t-PA,
especially in the elderly [10]. Recent outcome data (non-
randomized) from the Medicare database has suggested
little benefit, but possible harm, from thrombolysis in elderly
patients (>75 years old) in the USA [11]. The higher rate
of cerebral haemorrhage in elderly patients with t-PA (the
commonly preferred lytic agent in the US after the GUSTO
trial) might be responsible for this lack of benefit. Certainly
the Fibrinolytic Therapy Trialists’ overview (largely streptoki-
nase trials) [5] suggested a higher absolute benefit of
thrombolysis in older patients. We have emphasized the
importance of considering all the information available from
randomized controlled trials, rather than selective emphasis
on one subgroup in one trial [1,12].
Conclusion
Cardiologists have been at the forefront in carrying out
large randomized clinical trials. They have based their
practice on the evidence that has resulted from overviews
of these trials. However, this enthusiasm for trial evidence
may be harmful when subgroup analyses are carried out
without a proper appreciation of the statistical pitfalls.
Undue emphasis on a particular subgroup may result in
inappropriate treatment.
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